Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics

歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the annual report of Ocumension Therapeutics (the "Company") for the year ended December 31, 2024 (the "Annual Report"). Unless the context requires otherwise, capitalized terms used in this announcement shall bear the same meanings as defined in the Annual Report.

As disclosed in the Annual Report, as of December 31, 2024, 17,086,000 Shares were repurchased and held in treasury by the Company. Subsequently, and following a series of Share repurchases conducted by the Company, 20,949,500 Shares have been repurchased and are held in treasury as of the date of this announcement.

The Company would like to supplement that the treasury Shares repurchased and held by the Company are intended to be used in accordance with the applicable rules and regulations, including but not limited to sale for cash, transfer and cancellation.

The above information does not affect the information disclosed in the Annual Report and save as disclosed in this announcement, all other information in the Annual Report remains unchanged.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, December 19, 2025

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.